ClinicalTrials.gg
CompletedNCT02195583Updated May 1, 2015Results posted

The Effect of Experimental Dentifrices on Remineralization of Caries Lesions In-situ

An interventional study of Sodium fluoride (1426 ppm) and Sodium fluoride (1150 ppm) in Oral Hygiene, sponsored by GlaxoSmithKline. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-05-01.

Sponsored by GlaxoSmithKline · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study will evaluate the effect of experimental sodium fluoride-silica dentifrice formulations, with and without zinc, on remineralization of enamel in situ. Following the remineralization phase, the acid resistance of the new mineral formed will be assessed. Fluoride uptake during the remineralization phase will also be measured.

02

Conditions studied

  • Oral Hygiene
03

In context

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.

Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Good general health with no and relevant abnormalities of medical history or oral examination
  • Participants with maxillary dental arch suitable for the retention of the palatal appliance

Exclusion criteria

Exclusion Criteria:

  • Participants taking fluoride supplement
  • Pregnant or breast-feeding women
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    Sodium fluoride (1426 ppm)

    Non-zinc, 1426ppm fluoride as sodium fluoride in a silica gel base

    Drug: Sodium fluoride (1426 ppm)

  • Experimental
    Sodium fluoride (1150 ppm)

    Non-zinc, 1150ppm fluoride as sodium fluoride in a silica gel base

    Drug: Sodium fluoride (1150 ppm)

  • Experimental
    Sodium fluoride (250 ppm)

    Non-zinc, 250ppm fluoride as sodium fluoride in a silica gel base

    Drug: Sodium fluoride (250 ppm)

  • Experimental
    Sodium fluoride (1426 ppm) + zinc base A

    Zinc base A, 1426ppm fluoride as sodium fluoride in a silica gel base

    Drug: Sodium fluoride (1426 ppm) + zinc base A

  • Experimental
    Sodium fluoride (1426 ppm) + zinc base B

    Zinc base B, 1426ppm fluoride as sodium fluoride in a silica gel base

    Drug: Sodium fluoride (1426 ppm) + zinc base B

  • Placebo comparator
    Fluoride (0 ppm)

    Non-zinc, 0ppm fluoride in a silica gel base

    Drug: Fluoride (0 ppm)

Interventions

  • Non-zinc, 1426ppm fluoride as sodium fluoride in a silica gel base

  • Non-zinc, 1150ppm fluoride as sodium fluoride in a silica gel base

  • Non-zinc, 250ppm fluoride as sodium fluoride in a silica gel base

  • DrugSodium fluoride (1426 ppm) + zinc base A

    Zinc base A, 1426ppm fluoride as sodium fluoride in a silica gel base

  • DrugSodium fluoride (1426 ppm) + zinc base B

    Zinc base B, 1426ppm fluoride as sodium fluoride in a silica gel base

  • DrugFluoride (0 ppm)

    Non-zinc, 0ppm fluoride in a silica gel base

06

What researchers measure

Primary outcomes

  1. Percentage Surface Microhardness Recovery (% SMHR)

    Changes in the mineral content of the four centrally-located enamel specimens were evaluated using the Surface Microhardness (SMH) Test. The SMH was measured using a Wilson 2100 Hardness Tester. The baseline SMH was determined prior to the in vitro acid challenge. SMH was determined again after the in vitro acid challenge, after the in situ remineralization test, and again after the second in vitro acid challenge. The extent of remineralization was calculated as the % recovery in SMH using the equation: % SMHR= \[(D1-R)/(D1-B)\]\*100 Where B = indentation length (μm) of sound enamel at baseline; D1 = indentation length (μm) after first acid challenge; R = indentation length (μm) after in situ remineralization.

    Time frame: Baseline to 4 hours

Secondary outcomes

  1. Enamel Fluoride Uptake

    The microdrill enamel biopsy technique was used to analyze the fluoride uptake by enamel. Each enamel specimen was mounted on the long axis of a drill attached to a microdrill and drilled to a depth of approximately 100 micrometer (μm) through the entire lesion (four cores per specimen). The enamel powder pooled from four drilling sample was then immediately analyzed for fluoride content using fluoride specific electrode and pH/ion meter. The amount of fluoride-uptake by enamel was calculated based on the amount of fluoride divided by the area of the enamel cores and expressed as microgram per square centimeter (μg/cm\^2).

    Time frame: Baseline to 4 hours

  2. Percentage Net Acid Resistance (% NAR)

    Changes in the mineral content of the four centrally-located enamel specimens were evaluated using the SMH Test. The SMH was measured using a Wilson 2100 Hardness Tester. The baseline SMH was measured prior to the in vitro acid challenge. SMH was measured again after the in vitro acid challenge, after the in situ remineralization test, and again after the second in vitro acid challenge. The % NAR was calculated using the equation: % NAR= \[(D1-D2)/(D1-B)\]\*100 where B= Indentation length (μm) of sound enamel at baseline; D1= Indentation length (μm) after first acid challenge and D2= Indentation length (μm) after second acid challenge.

    Time frame: Baseline to 4 hours

  3. Percentage Comparative Acid Resistance (% CAR)

    Changes in the mineral content of the four centrally-located enamel specimens were evaluated using the SMH Test. The SMH was measured using a Wilson 2100 Hardness Tester. The baseline SMH was measured prior to the in vitro acid challenge. SMH was measured again after the in vitro acid challenge, after the in situ remineralization test, and again after the second in vitro acid challenge. The % CAR was calculated using the equation: % CAR= \[(D2-R)/(D1-B)\]\*100 where B= Indentation length (μm) of sound enamel at baseline; R= Indentation length (μm) of enamel after in situ remineralization; D1= Indentation length (μm) after first acid challenge; D2= Indentation length (μm) after second acid challenge.

    Time frame: Baseline to 4 hours

07

Results

Posted Apr 7, 2015

Participant flow

Participants were recruited at one clinical study site in the USA.

Participant flow — Overall Study
MilestoneOverall Participants
Started62
Sodium fluoride (1150 ppm)57
Sodium fluoride (0 ppm)59
Sodium fluoride (1426 ppm) + zinc base a58
Sodium fluoride (250 ppm)55
Sodium fluoride (1426 ppm)59
Sodium fluoride (1426 ppm) + zinc base b60
Completed53
Not completed9
Withdrew: Lost to follow-up1
Withdrew: Withdrawal by subject4
Withdrew: Adverse event2
Withdrew: Other reason2

Outcome measures

PrimaryPercentage Surface Microhardness Recovery (% SMHR)

Changes in the mineral content of the four centrally-located enamel specimens were evaluated using the Surface Microhardness (SMH) Test. The SMH was measured using a Wilson 2100 Hardness Tester. The baseline SMH was determined prior to the in vitro acid challenge. SMH was determined again after the in vitro acid challenge, after the in situ remineralization test, and again after the second in vitro acid challenge. The extent of remineralization was calculated as the % recovery in SMH using the equation: % SMHR= \[(D1-R)/(D1-B)\]\*100 Where B = indentation length (μm) of sound enamel at baseline; D1 = indentation length (μm) after first acid challenge; R = indentation length (μm) after in situ remineralization.

Time frame:
Baseline to 4 hours
Reported as:
Least squares mean · Percentage of SMHR
Percentage Surface Microhardness Recovery (% SMHR)
Percentage of SMHRSodium Fluoride (1426 Ppm)Sodium Fluoride (1150 Ppm)Sodium Fluoride (250 Ppm)Sodium Fluoride (1426 Ppm) + Zinc Base ASodium Fluoride (1426 Ppm) + Zinc Base BSodium Fluoride (0 Ppm)
Percentage Surface Microhardness Recovery (% SMHR)32.49 ± 1.16731.81 ± 1.18227.56 ± 1.19922.62 ± 1.17523.22 ± 1.15924.78 ± 1.167
Statistical analysis
  • Sodium Fluoride (1426 Ppm) vs Sodium Fluoride (1150 Ppm) vs Sodium Fluoride (250 Ppm) · ANOVA · p = <0.0001Calculated from Analysis of Variance (ANOVA) model using treatment and study period as fixed factors and participant as random effect.
  • Sodium Fluoride (1426 Ppm) vs Sodium Fluoride (1150 Ppm) vs Sodium Fluoride (250 Ppm) · ANOVA · p = 0.2274Calculated from ANOVA model using treatment and study period as fixed factors and participant as random effect.
  • Sodium Fluoride (1426 Ppm) vs Sodium Fluoride (1150 Ppm) · ANOVA · p = 0.5950 · Mean difference (net): 0.68 · 95% CI -1.84 to 3.20Difference was calculated as Sodium fluoride (1426 ppm) minus Sodium fluoride (1150 ppm) such that a positive difference favors Sodium fluoride (1426 ppm).
  • Sodium Fluoride (1426 Ppm) vs Sodium Fluoride (250 Ppm) · ANOVA · p = 0.0002 · Mean difference (net): 4.93 · 95% CI 2.38 to 7.48Difference was calculated as Sodium fluoride (1426 ppm) minus Sodium fluoride (250 ppm) such that a positive difference favors Sodium fluoride (1426 ppm).
  • Sodium Fluoride (1150 Ppm) vs Sodium Fluoride (250 Ppm) · ANOVA · p = 0.0013 · Mean difference (net): 4.25 · 95% CI 1.68 to 6.82Difference was calculated as Sodium fluoride (1150 ppm) minus Sodium fluoride (250 ppm) such that a positive difference favors Sodium fluoride (1150 ppm).
  • Sodium Fluoride (1426 Ppm) vs Sodium Fluoride (0 Ppm) · ANOVA · p = <0.0001 · Mean difference (net): 7.71 · 95% CI 5.20 to 10.21Difference was calculated as Sodium fluoride (1426 ppm) minus Sodium fluoride (0 ppm) such that a positive difference favors Sodium fluoride (1426 ppm).
  • Sodium Fluoride (1150 Ppm) vs Sodium Fluoride (0 Ppm) · ANOVA · p = <0.0001 · Mean difference (net): 7.03 · 95% CI 4.51 to 9.55Difference was calculated as Sodium fluoride (1150 ppm) minus Sodium fluoride (0 ppm) such that a positive difference favors Sodium fluoride (1150 ppm).
  • Sodium Fluoride (250 Ppm) vs Sodium Fluoride (0 Ppm) · ANOVA · p = 0.0325 · Mean difference (net): 2.78 · 95% CI 0.23 to 5.32Difference was calculated as Sodium fluoride (250 ppm) minus Sodium fluoride (0 ppm) such that a positive difference favors Sodium fluoride (250 ppm).
  • Sodium Fluoride (1426 Ppm) + Zinc Base A vs Sodium Fluoride (0 Ppm) · ANOVA · p = 0.0920 · Mean difference (net): -2.16 · 95% CI -4.67 to 0.35Difference was calculated as 'Sodium fluoride (1426 ppm) + zinc base A' minus Sodium fluoride (0 ppm) such that a positive difference favors 'Sodium fluoride (1426 ppm) + zinc base A'.
  • Sodium Fluoride (1426 Ppm) + Zinc Base B vs Sodium Fluoride (0 Ppm) · ANOVA · p = 0.2185 · Mean difference (net): -1.56 · 95% CI -4.04 to 0.93Difference was calculated as 'Sodium fluoride (1426 ppm) + zinc base B' minus Sodium fluoride (0 ppm) such that a positive difference favors 'Sodium fluoride (1426 ppm) + zinc base B'.
  • Sodium Fluoride (1426 Ppm) vs Sodium Fluoride (1426 Ppm) + Zinc Base A · ANOVA · p = <0.0001 · Mean difference (net): 9.87 · 95% CI 7.36 to 12.37Difference was calculated as Sodium fluoride (1426 ppm) minus 'Sodium fluoride (1426 ppm) + zinc base A' such that a positive difference favors Sodium fluoride (1426 ppm).
  • Sodium Fluoride (1426 Ppm) vs Sodium Fluoride (1426 Ppm) + Zinc Base B · ANOVA · p = <0.0001 · Mean difference (net): 9.26 · 95% CI 6.77 to 11.75Difference was calculated as Sodium fluoride (1426 ppm) minus 'Sodium fluoride (1426ppm) + zinc base B' such that a positive difference favors Sodium fluoride (1426 ppm).
SecondaryEnamel Fluoride Uptake

The microdrill enamel biopsy technique was used to analyze the fluoride uptake by enamel. Each enamel specimen was mounted on the long axis of a drill attached to a microdrill and drilled to a depth of approximately 100 micrometer (μm) through the entire lesion (four cores per specimen). The enamel powder pooled from four drilling sample was then immediately analyzed for fluoride content using fluoride specific electrode and pH/ion meter. The amount of fluoride-uptake by enamel was calculated based on the amount of fluoride divided by the area of the enamel cores and expressed as microgram per square centimeter (μg/cm\^2).

Time frame:
Baseline to 4 hours
Reported as:
Least squares mean · microgram per square centimeter(μg/cm^2)
Enamel Fluoride Uptake
microgram per square centimeter(μg/cm^2)Sodium Fluoride (1426 Ppm)Sodium Fluoride (1150 Ppm)Sodium Fluoride (250 Ppm)Sodium Fluoride (1426 Ppm) + Zinc Base ASodium Fluoride (1426 Ppm) + Zinc Base BSodium Fluoride (0 Ppm)
Enamel Fluoride Uptake2.94 ± 0.0832.70 ± 0.0841.85 ± 0.0852.62 ± 0.0832.37 ± 0.0820.98 ± 0.083
SecondaryPercentage Net Acid Resistance (% NAR)

Changes in the mineral content of the four centrally-located enamel specimens were evaluated using the SMH Test. The SMH was measured using a Wilson 2100 Hardness Tester. The baseline SMH was measured prior to the in vitro acid challenge. SMH was measured again after the in vitro acid challenge, after the in situ remineralization test, and again after the second in vitro acid challenge. The % NAR was calculated using the equation: % NAR= \[(D1-D2)/(D1-B)\]\*100 where B= Indentation length (μm) of sound enamel at baseline; D1= Indentation length (μm) after first acid challenge and D2= Indentation length (μm) after second acid challenge.

Time frame:
Baseline to 4 hours
Reported as:
Least squares mean · Percentage of NAR
Percentage Net Acid Resistance (% NAR)
Percentage of NARSodium Fluoride (1426 Ppm)Sodium Fluoride (1150 Ppm)Sodium Fluoride (250 Ppm)Sodium Fluoride (1426 Ppm) + Zinc Base ASodium Fluoride (1426 Ppm) + Zinc Base BSodium Fluoride (0 Ppm)
Percentage Net Acid Resistance (% NAR)-12.54 ± 1.224-13.45 ± 1.244-17.81 ± 1.266-17.60 ± 1.234-18.98 ± 1.214-50.60 ± 1.224
SecondaryPercentage Comparative Acid Resistance (% CAR)

Changes in the mineral content of the four centrally-located enamel specimens were evaluated using the SMH Test. The SMH was measured using a Wilson 2100 Hardness Tester. The baseline SMH was measured prior to the in vitro acid challenge. SMH was measured again after the in vitro acid challenge, after the in situ remineralization test, and again after the second in vitro acid challenge. The % CAR was calculated using the equation: % CAR= \[(D2-R)/(D1-B)\]\*100 where B= Indentation length (μm) of sound enamel at baseline; R= Indentation length (μm) of enamel after in situ remineralization; D1= Indentation length (μm) after first acid challenge; D2= Indentation length (μm) after second acid challenge.

Time frame:
Baseline to 4 hours
Reported as:
Least squares mean · Percentage of CAR
Percentage Comparative Acid Resistance (% CAR)
Percentage of CARSodium Fluoride (1426 Ppm)Sodium Fluoride (1150 Ppm)Sodium Fluoride (250 Ppm)Sodium Fluoride (1426 Ppm) + Zinc Base ASodium Fluoride (1426 Ppm) + Zinc Base BSodium Fluoride (0 Ppm)
Percentage Comparative Acid Resistance (% CAR)45.00 ± 1.27445.23 ± 1.29545.44 ± 1.31940.29 ± 1.28542.21 ± 1.26475.41 ± 1.274

Adverse events

Collected over Adverse Events (AEs) were collected from the start of the investigational product (or washout product) and until five days following last administration of the investigational product.Serious adverse events (SAEs) were collected over the same time period.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sodium Fluoride (1426 Ppm)—0/59 (0%)3/59 (5.1%)
Sodium Fluoride (1150 Ppm)—0/57 (0%)1/57 (1.8%)
Sodium Fluoride (250 Ppm)—0/55 (0%)5/55 (9.1%)
Sodium Fluoride (1426 Ppm) + Zinc Base A—0/58 (0%)1/58 (1.7%)
Sodium Fluoride (1426 Ppm) + Zinc Base B—1/60 (1.7%)4/60 (6.7%)
Sodium Fluoride (0 Ppm)—0/59 (0%)5/59 (8.5%)
Most frequent serious events
Most frequent serious events
EventSodium Fluoride (1426 Ppm)Sodium Fluoride (1150 Ppm)Sodium Fluoride (250 Ppm)Sodium Fluoride (1426 Ppm) + Zinc Base ASodium Fluoride (1426 Ppm) + Zinc Base BSodium Fluoride (0 Ppm)
Adenocarcinoma of colonNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/590/570/550/581/600/59
Most frequent other events
Showing 10 of 13
Most frequent other events
EventSodium Fluoride (1426 Ppm)Sodium Fluoride (1150 Ppm)Sodium Fluoride (250 Ppm)Sodium Fluoride (1426 Ppm) + Zinc Base ASodium Fluoride (1426 Ppm) + Zinc Base BSodium Fluoride (0 Ppm)
Oral Mucosal ErythemaGastrointestinal disorders2/590/570/550/581/602/59
Abdominal DiscomfortGastrointestinal disorders0/590/571/550/580/600/59
NasopharyngitisInfections and infestations0/590/571/550/581/601/59
HeadacheNervous system disorders0/590/571/550/580/600/59
PalpitationsCardiac disorders0/590/571/550/580/600/59
Intervertebral disc degenerationMusculoskeletal and connective tissue disorders0/590/571/550/580/600/59
DysmenorrhoeaReproductive system and breast disorders0/591/570/550/580/600/59
Motion sicknessEar and labyrinth disorders0/590/570/551/580/600/59
Lymph gland infectionInfections and infestations1/590/570/550/580/600/59
Meniscus injuryInjury, poisoning and procedural complications0/590/570/550/580/601/59

Baseline characteristics

All randomized participants were evaluated for baseline characteristics

Age, Continuous
Age, Continuous(Years)All Randomized Participants
Mean40.7 ± 12.03
Sex: Female, Male
Sex: Female, Male(Participants)All Randomized Participants
Female39
Male23
08

Study locations

1 site
  • GSK Investigational Site
    Indianapolis, Indiana 46202, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2014, a primary completion of Aug 2014 and a completion of Aug 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2015, 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2014
First posted
Jul 21, 2014
Start
Jun 2014
Primary completionActual
Aug 2014
CompletionActual
Aug 2014
Results first posted
Apr 7, 2015
Last update
May 1, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02195583
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 21, 2014
Start date
Jun 2014
Primary completion
Aug 2014
Completion
Aug 2014
Results posted
Apr 7, 2015
Last update
May 1, 2015

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sodium Fluoride

Start the discussion